- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01865461
Evaluation of MRI Sequences in Hepatic Overload (HEPAT_MR)
March 10, 2021 updated by: Rennes University Hospital
Evaluation of MRI Sequences in Hepatic Overload.
MRI, without any contrast injection, allows a non-invasive evaluation and quantification of hepatic overloads, especially iron (liver iron content LIC) and fat (steatosis) overloads, but in certain clinical circumstances, cases require to improve performances.
The aim of the study is to add to MRI scans which currently must be performed innovative sequences appropriate for the clinical question to overall appreciate on a varied range of patients their quality, their robustness, their relative performance and, for patients having a biopsy, their accuracy.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
706
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Rennes, France, 35033
- Rennes University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with or suspected clinically to be with a hepatic overload pathology (hepatic iron and/or fat overload)
Description
Inclusion Criteria:
- Men and women ≥ 18 years of age
- Patients with or suspected clinically to be with a hepatic overload pathology (hepatic iron and/or fat overload) and who need a diagnostic or pre-therapeutic MRI from his initial management or during his monitoring,
- Patient able to provide written informed consent and can understand and comply with the requirements of the study
- Patient having received the information about the protocol and having not expressed his opposition to participate.
Exclusion Criteria:
Due to MRI :
- pacemaker or defibrillator,
- MRI non-compatible heart valve,
- clips, stents, coils, etc… non-compatible with MRI,
- cochlear implants,
- neuronal or peripheric simulator,
- intra-orbital or encephalic metallic foreign body, foreign body close to eyes, foreign body near the eyes, injury by metallic luster (war, ball),
- endoprosthesis received since less than 4weeks and osteosynthesis equipment received since less than 6 weeks,
- claustrophobia,
- pump, tattoo, permanent make-up, intrauterine device, patch,
- metal, magnetic, non-removable and in the area of the analyse field material
Other criteria :
- unstable hemodynamic state, acute respiratory insufficiency, hemodynamically unstable acute respiratory failure, poor general condition or the necessity of a continuous monitoring incompatible with the MRI constraint,
- adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty,
- pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of the quantification deviations of hepatic iron and fat overloads between the new sequences and the conventional sequences.
Time Frame: 18 months
|
Evaluation of the robustness and the relative accuracy, comparison of sequences currently performed in daily clinical practice, of hepatic iron and fat content quantification with non-invasive new abdominal MRI sequences.
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Analysis of the accuracy of quantification: of the iron concentration against biochemical, semi-quantitative histological or subtracted iron volume compared to the hepatic volume analysis
Time Frame: 18 months
|
Evaluation of the accuracy of these new MRI sequences for hepatic iron and fat quantification, when patients have had in their normal care and management a biopsy or a bleedings subtracted iron volume leading to a desaturation.
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 4, 2013
Primary Completion (Actual)
December 19, 2018
Study Completion (Actual)
December 19, 2018
Study Registration Dates
First Submitted
May 27, 2013
First Submitted That Met QC Criteria
May 30, 2013
First Posted (Estimate)
May 31, 2013
Study Record Updates
Last Update Posted (Actual)
March 11, 2021
Last Update Submitted That Met QC Criteria
March 10, 2021
Last Verified
March 1, 2020
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2013-A00197-38
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Iron and Fat Hepatic Overload
-
Rennes University HospitalCompletedIron Hepatic Overload | Fat Hepatic OverloadFrance
-
Assiut UniversityCompleted
-
University of Wisconsin, MadisonNational Institute for Biomedical Imaging and Bioengineering (NIBIB)RecruitingHealthy | Iron Overload | Liver FatUnited States
-
Novartis PharmaceuticalsCompletedTransfusional Iron OverloadItaly
-
ApoPharmaCompletedTransfusional Iron OverloadEgypt, Cyprus, Oman, Saudi Arabia, Turkey
-
Novartis PharmaceuticalsCompletedChronic Iron OverloadGermany
-
Novartis PharmaceuticalsCompletedCardiac Iron OverloadTaiwan, Egypt, Thailand, Turkey, United Kingdom, Italy, Canada, Greece
-
ApoPharmaCompletedIron Overload Due to Repeated Red Blood Cell TransfusionsUnited States, Canada, Greece, Italy
-
Assiut UniversityUnknownPlatelet Changes in Cases of Iron Overload
-
Novartis PharmaceuticalsCompleted